Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00512096 · ClinicalTrials.gov registry record · Phase 2
Neoadjuvant Chemotherapy for Patients With Squamous Cell Carcinoma of the Penis
A Phase 2 study, sponsored by M.D. Anderson Cancer Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 30
- Enrollment target
NCT00512096: Completed Phase 2 study, sponsored by M.D. Anderson Cancer Center.
NCT00512096 is a Phase 2 study that has completed, run by M.D. Anderson Cancer Center. The registered enrollment target is 30 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00512096, a Phase 2 study, has completed, sponsored by M.D. Anderson Cancer Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 30 participants
- Enrollment target
Study Summary
Primary Objective: -To evaluate the feasibility and efficacy of multimodality treatment (neoadjuvant chemotherapy prior to extirpative surgery) for clinical stage TXN2-3M0 squamous cell carcinoma of the penis.
Interventions
- DRUG Cisplatin
- DRUG Ifosfamide
- DRUG Paclitaxel (Taxol)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 1999-08 |
| Est. Completion | 2010-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00512096
The ClinicalTrials.gov registry entry for NCT00512096 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Cisplatin is the first listed.
NCT00512096 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00512096 about?
NCT00512096 is a clinical study titled "Neoadjuvant Chemotherapy for Patients With Squamous Cell Carcinoma of the Penis". Primary Objective: -To evaluate the feasibility and efficacy of multimodality treatment (neoadjuvant chemotherapy prior to extirpative surgery) for clinical stage TXN2-3M0 squamous cell carcinoma of the penis.
What is the current status of trial NCT00512096?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 30 participants. The study started on 1999-08. Estimated completion is 2010-08.
What interventions are being tested in trial NCT00512096?
The interventions under investigation include: Cisplatin (DRUG), Ifosfamide (DRUG), Paclitaxel (Taxol) (DRUG).
Who is sponsoring clinical trial NCT00512096?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.